论文部分内容阅读
目的探讨利拉鲁肽治疗新疆维吾尔族2型糖尿病(T2DM)肥胖患者的疗效。方法纳入67例单用二甲双胍后血糖控制不理想的肥胖T2DM患者,将其随机分为二甲双胍组(单用二甲双胍)和二甲双胍+利拉鲁肽组(联合应用二甲双胍和利拉鲁肽),治疗周期为12周。分别在基线、治疗12周后检测2组患者腹部内脏脂肪面积(VA)、体脂百分比(PBF)、体脂肪量,同时测量一氧化氮(NO)、空腹血糖(FBG)、糖化血红蛋白(HbA1c)、游离脂肪酸(FFA)等相关指标,计算体质量指数(BMI)、腰臀比(WHR),采取病例对照的试验方法进行分析。结果治疗12周后,二甲双胍+利拉鲁肽组较二甲双胍组,患者体质量(W)、WHR、腰围(WC)、空腹血糖(FBG)、体脂肪量和腹内脂肪(VA)均明显下降,差异有统计学意义(P<0.05)。结论接受利拉鲁肽治疗的T2DM肥胖患者在血糖、血脂得到控制的同时,能获得降低W、改善血管内皮功能、减少内脏脂肪的收益。
Objective To investigate the efficacy of liraglutide in the treatment of type 2 diabetes mellitus (T2DM) obesity in Xinjiang Uygur Autonomous Region. Methods A total of 67 obese T2DM patients with unsatisfactory glycemic control after metformin were enrolled. The patients were randomly divided into metformin group (metformin alone) and metformin plus liraglutide group (metformin and liraglutide combination) For 12 weeks. The levels of abdominal visceral fat area (VA), body fat percentage (PBF) and body fat in the two groups were measured at baseline and 12 weeks after treatment respectively. Nitric oxide (NO), fasting blood glucose (FBG), HbA1c ), Free fatty acid (FFA) and other related indicators, body mass index (BMI) and waist-hip ratio (WHR) were calculated and analyzed by case-control test. Results After treatment for 12 weeks, the body weight (W), WHR, WC, FBG, body fat and intra-abdominal fat (VA) decreased significantly in the metformin + liraglutide group compared with the metformin group , The difference was statistically significant (P <0.05). Conclusion T2DM obese patients treated with liraglutide can gain the benefits of reducing W, improving endothelial function and reducing visceral fat while controlling blood sugar and blood lipid.